ASC Biosciences, Inc.

Incorporated in Nevada - November 28, 2007

Financial Statements

For the 6 Months Ended

June 30, 2018

Statements issued and prepared by Management

ASC Biosciences, Inc.

Financial Statements

Table of Contents

Yu Certified Public Accountant, P.C.
Professionalism, Expertise, Integrity

AUTHORIZATION TO FILE FORM 10-Q

Please be advised that we have completed our quarterly review of the consolidated balance sheet of ASC Biosciences, Inc. as of June 30, 2018, and the related consolidated statements of operations and comprehensive income (loss) and cash flows for the quarterly period ended June 30, 2018. We conducted our quarterly review in accordance with Statement on Auditing Standards No.100 and other applicable standards of the Public Company Accounting Oversight Board (US) and consent to the filing of the above-mentioned report.

We have not reviewed the EDGARized version of the Form 10-Q, nor have we reviewed the Company's XBRL-related documents. It is your responsibility to proofread and math check the EDGARized version of the Form 10-Q to ensure it conforms exactly to the Microsoft Word version dated June 30, 2018, which has been reviewed.

If the financial statements are not issued today (as defined in ASC 855-10-S99-2), we are required to update our procedures, and the above-mentioned document should not be filed with the SEC.

As always, it was a pleasure to be of service to your organization.

Yu Certified Public Accountant P.C.

Yu Certified Public Accountant P.C.

7/19/2018

Certified Public Accountants
99 Madison Avenue, Suite 601, New York NY 10016
Tel: 347-618-9237, 718-813-2130
Email: Info@ywlcpa.com

ASC Biosciences, Inc.

(Formerly Nevis Capital Corporation)

Balance Sheets

	June 30, 2018	December 31, 2017
ASSETS		
Current assets		
Checking/Savings		
Cash at Bank - Checking Account	**144,838**	*239,777*
Cash at Bank - Savings Account	**100,016**	*21,998*
Cash at Bank - Payroll Account	**86,043**	-
Bank & Cash Total	**$ 330,897**	**$ 261,775**
Other Current Assets		
Miscellaneous Receivables	**0**	-
Deposits & Prepayments	**6,487**	-
Total current assets	**$ 337,384**	**$ -**
Fixed Assets		
Furniture, Fixtures & Equipment	**54,127**	*54,127*
Accumulated Depreciation	**(6,766)**	*(1,353)*
Total Fixed Assets	**$ 47,361**	**$ 52,774**
Total Assets	**$ 384,745**	**$ 314,549**
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current Liabilities		
Accounts Payable	**0**	-
Payroll Liabilities	**0**	*147*
Accrued Expenses	**0**	*66,184*
Wells Fargo Credit Line	**1,518**	*7,120*
Investor Deposits	**0**	*763,750*
Total current liabilities	**$ 1,518**	***$ 837,201***
Long Term Liabilities		
Officer and Shareholder Loans	-	-
Equipment Loans	**23,647**	*26,584*
Total Long Term Liabilities	**$ 23,647**	***$ 26,584***
Total liabilities	**$ 25,165**	***$ 863,785***
Members' equity (deficit)		
Common stock, $.001 par value; 50,000,000 (Reduced from 981,675,380) shares authorized. 8,030,780 and 8,030,780 shares issued and 6,258,384 and 6,438,780 outstanding as of June 30, 2018 and June 30, 2017. Common Shares Reverse Split 1 for 2000 on May 9, 2017.		
Common Stock Issued	**8,031**	*8,031*
Treasury Shares	**(1,772)**	*(2,400)*
Common Stock Outstanding	**6,258**	*5,631*
Additional Paid in Capital	**1,210,647**	-
Retained Earnings	**(554,867)**	*(554,867)*
Accumulated Surplus / (Deficit) Current Year	**(302,459)**	-
Total stockholders' deficit	**$ 359,580**	***$ (549,236)***
Total liabilities and Stockholders' Deficit	**$ 384,745**	***$ 314,549***

The accompanying notes are an integral part of these Financial Statements

ASC Biosciences, Inc.

(Formerly Nevis Capital Corporation)

Consolidated Statement of Operations

	For the Three Months ended June 30, 2018	For the Three Months ended June 30, 2017	For the Six Months ended June 30, 2018	For the Six Months ended June 30, 2017
Revenue				
Wholesale Cell Sales	-	-	-	-
Offshore Clinic Income	-	-	-	-
Total Revenue	$ -	$ -	$ -	$ -
Cost of Goods Sold	-	-	-	-
Gross Profit / (Loss) from operations	$ -	$ -	$ -	$ -
Overhead Expenses				
Total Advertising Expenses	$ 964	$ 2,258	$ 7,142	$ 2,258
Total Vehicle Expenses	$ -	$ -	$ -	$ -
Total Misc. Overhead Expense	$ 9,271	$ 15	$ 22,912	$ 15
Total Independent Contractor Fees	$ 15,000	$ 7,000	$ 60,000	$ 7,000
Total Professional Fees	$ 35,081	$ 6,768	$ 67,938	$ 6,768
Total Office Expenses	$ 1,332	$ 250	$ 5,098	$ 250
Total Utility Expense	$ 456	$ -	$ 784	$ -
Total Rent Expense	$ -	$ -	$ -	$ -
Total Payroll Expense	$ 68,119	$ -	$ 136,808	$ -
Total Overhead Expenses	$ 130,223	$ 16,291	$ 300,682	$ 16,291
Profit / (Loss) from Operations	$ (130,223)	$ (16,291)	$ (300,682)	$ (16,291)
Other Income / (Expenses)				
Interest Income	16	-	16	-
Interest expense	(542)	(118)	(993)	(118)
Taxation & Dividends				
State Income Taxes	28	0	(800)	
Total other income / (expenses)	$ (498)	$ (118)	$ (1,777)	$ (118)
Net Profit / (Loss)	$ (130,721)	$ (16,409)	$ (302,459)	$ (16,409)
Net loss per common share - basic and diluted	($0.02)		($0.05)	$0.00
Weighted average shares outstanding	6,258,380	6,430,780	6,258,380	6,430,780

The accompanying notes are an integral part of these financial statements

ASC Biosciences, Inc.

(Formerly Nevis Capital Corporation)

CONSOLIDATED STATEMENT OF CASH FLOWS

Cash Flows from Operating Activities	**6 Months Ended June 30, 2018**	***6 Months Ended 6/30/2017***
Net Profit / (Loss)	**$ (302,459)**	***$ (16,409)***
Adjustments to reconcile net loss to net cash used in operating activities:		
Accounts Receivable & Pre-paid Expenses	**(6,487)**	*-*
Accumulated Depreciation - FF & E	**5,413**	*-*
Business Credit Line	**(5,603)**	***9,713***
Accounts Payable & Accrued Expenses	**(66,331)**	***119***
Other Business Loans Payable	**(2,936)**	***250***
Net Cash Used in Operating Activities:	**$ (378,403)**	***$ (6,327)***
Cash Flows from Investing Activities:		
Organization Costs - Nevis Capital	**-**	***(90,631)***
	$ (378,403)	***$ (86,876)***
Cash Flows from Financing Activities:		
Common Stock Issued at Par Value	**-**	***(41,168)***
Additional Paid In Capital	**-**	***49,154***
Treasury Stock at Cost	**-**	***6,900***
Retained Earnings	**-**	***(25,173)***
Investor Deposits	**447,525**	***113,750***
	$ 447,525	***$ 103,463***
Net Increase / (Decrease) in Cash and Cash Equivalents:	**69,122**	***10,260***
CASH BALANCE AT BEGINNING OF PERIOD:	**261,775**	*-*
CASH BALANCE AT END OF PERIOD:	**$ 330,897**	***$ 10,260***

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

Cash Paid for Interest	***$ 993***	***$ -***
Cash Paid for Taxes	***$ 800***	***$ -***

The accompanying notes are an integral part of these financial statements

ASC Biosciences, Inc.

(Formerly Nevis Capital Corporation)

Statement of Stockholders Equity

(Unaudited)

	Common Shares Post-Split	Stock $ Amnt @ Par	Treasury Stock	Additional Paid in Capital	Retained Deficit	Stockholders' Equity
Balances - April 30, 2016	*15,059*	$ 30,117	$ (8,500)	$ 25,412,150	$ (84,654)	$ 25,349,113
Stock Issued to pay Creditor	*13*	$ 25		$ 1,000		$ 1,025
Stock Issued for Oil Interests	*1,000*	$ 2,000		$ 80,000		$ 82,000
Stock Issued for Professional Services	*313*	$ 625		$ 25,000		$ 25,625
Stock Issued for Investor	*250*	$ 500		$ 10,000		$ 10,500
Stock Issued for JV - Young	*841*	$ 1,682		$ 185,031		$ 186,713
Stock Issued for Arbit Media	*6,250*	$ 12,500		$ 125,000		$ 137,500
Stock Issued for Bougainville	*500*	$ 1,000		$ 20,000		$ 21,000
Loss for 12 Month Period:				$ (18,332)	$ (25,406,500)	$ (25,424,832)
Balances - April 30, 2016	*24,225*	$ 48,449	$ (8,500)	$ 25,839,849	$ (25,491,154)	**$ 388,644**
Stock Issued for Professional Services	*375*	$ 750			$ (750)	$ -
Transfer of Assets to Court Receiver					$ (388,644)	$ (388,644)
Balances - July 31, 2016	*24,600*	$ 49,199	$ (8,500)	$ 25,839,849	$ (25,880,548)	$ -
Stock Issued for Professional Services						$ -
Loss for 3 Month Period:						$ -
Balances - October 31, 2016	*24,600*	$ 49,199	$ (8,500)	$ 25,839,849	$ (25,880,548)	$ -
Stock Issued for Professional Services						$ -
Loss for 3 Month & 27 day Period:						$ -
Balances - February 27, 2017	*24,600*	$ 49,199	$ (8,500)	$ 25,839,849	$ (25,880,548)	$ -
Loss for 32 day Period:						$ -
Balances - March 31, 2017	*24,600*	$ 49,199	$ (8,500)	$ 25,839,849	$ (25,880,548)	$ -

ASC Biosciences, Inc.

(Formerly Nevis Capital Corporation)

Statement of Stockholders Equity - (Continued)

(Unaudited)

Balances Brought Down:	*24,600*	49,199	(8,500)	25,839,849	(25,880,548)	0
*Reverse Stock Spli - 1 for 2000 ***	*0*	$ (49,174)	$ -	$ 49,154		$ (20)
issued due to rounding up fractional o'ships	*110*	$ -				$ -
Nevis Treasury Stock unaccounted for - w/off			$ 8,500			$ 8,500
Shares Cancelled by Court - Bougainville	*(500)*	$ -		$ -		$ -
***New** Shares Cancelled by Court - Topaiyo*	*(500)*	$ (1)		$ -		$ (1)
***New** Shares Cancelled by Court - Arbit Media*	*(6,250)*	$ (6)		$ -		$ (6)
***New** Shares Cancelled by Court - 111d.com*	*(6,680)*	$ (7)		$ -		$ (7)
***New** Shares Issued by Court Order - Johnson*	*20,000*	$ 20		$ -		$ 20
***New** Shares Issued by Court Order - Control Group*	*8,000,000*	$ 8,000	$ (1,600)	$ -		$ 6,400
Original ASC Assets & Liabilities Merged with Nevis		$ -	$ -	$ -	$ (25,173)	$ (25,173)
Net Loss for 3 Month Period:				$ -	$ (16,409)	$ (16,409)
Balances - June 30, 2017	*8,030,780*	$ 8,031	$ (1,600)	$ 25,889,003	$ (25,922,130)	**$ (26,696)**
Additionl Nevis Acquisition Adjustments		$ -	$ -	$ (25,889,003)	$ 25,905,721	$ 16,718
Additional Treasury Stock held for Investor		$ -	$ (800)	$ -	$ -	$ (800)
Retained Earnings 2015/2016 from "old" ASC		$ -	$ -	$ -	$ (1,371)	$ (1,371)
Net Loss for 3 Month Period:		$ -	$ -	$ -	$ (172,381)	$ (172,381)
Balances - September 30, 2017	*8,030,780*	$ 8,031	$ (2,400)	$ -	$ (206,570)	**$ (184,530)**
Net Loss for 3 Month Period:		$ -	$ -	$ -	$ (364,706)	$ (364,706)
Balances - December 31, 2017	*8,030,780*	$ 8,031	$ (2,400)	$ -	$ (571,276)	**$ (549,236)**
Net Loss for 3 Month Period:		$ -	$ -	$ -	$ (171,738)	$ (171,738)
Balances - March 31, 2018	*8,030,780*	$ 8,031	$ (2,400)	$ -	$ (743,014)	**$ (720,974)**
Net Loss for 3 Month Period:		$ -	$ -	$ -	$ (130,721)	$ (130,721)
Shares Issued to Stem Cell Development Fund, LLC		$ -	$ 628	$ 1,210,647	$ -	$ 1,211,275
Balances - June 30, 2018	*8,030,780*	$ 8,031	$ (1,772)	$ 1,210,647	$ (873,735)	**$ 359,580**

NOTE: 6,258,384 o/s + 1,772,396 Treas = 8,030,780 issued.

The accompanying notes are an integral part of these financial statements

ASC Biosciences, Inc.
(Formerly Nevis Capital Corporation)

NOTES TO FINANCIAL STATEMENTS

June 30, 2018

NOTE 1 –Operations

Organization and Description of Business

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs") will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans.

MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response, and thus can be used allogenically – which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands or millions of patients.

ASC believes it has a sustainable competitive advantage with its MASCs. Once FDA approved, the Company's MASCs will replace the need to use autologous stem cells for therapies.

The MASCs will essentially become known as "cells in a bottle", providing a specified dose of adult stem cells for specific therapies, which is an enormous advantage over harvesting cells from a patient's body. ASC intends to establish an intellectual property portfolio that will proprietary dominion in the repair and regeneration of all human tissues.

For more information visit: http://www.ascbio.com or @ASCbio1 on Facebook.

ASC Biosciences, Inc. was incorporated in Nevada on November 28, 2007 as Ocean Energy, Inc. for the purpose of producing and distributing Ocean Power Converters ("OPC") and supplying sea shore consumers. In November 2012 the company announced plans to change direction and become an investment holding company.

Also effective July 5, 2013, the Company changed its name from Sino Cement, Inc. to Nevis Capital Corporation. Previously, in September 2010, the Company had changed its name from "Ocean Energy, Inc." to "Sino Cement, Inc.". This name change came from a merger with a wholly owned subsidiary Sino Cement, Inc. This entity was formed solely for a name change.

NOTE 2 – Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The financial statements and notes are representations of the Company's management, who are responsible for their integrity and objectivity. The accounting policies conform to general accepted accounting principles in the United States of America and have been consistently applied in the preparation thereof. The Company's year- end was changed by ASC to December 31.

The relevant accounting policies and procedures are listed hereafter

Use of Estimates

The preparation of financial statements to be in conformity with general accepted accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Management is also responsible for disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include all short-term liquid investments that are readily convertible to cash and have original maturities of nine months or less.

Fixed Assets

In the 3 Months ended June 30, 2018, no additional Fixed Assets were acquired by The Company.

Intangible Assets

Through the medium of a license agreement ("License Agreement") with New York Medical College ("NYMC") for use of intellectual property, The Company controls patent number 7,259,011 whose technological basis will be used to create a range of orthopedic medical treatments using multi-potent adult stem cells (MASCs). More information on this technology and the Company's business plan can be found on The Company's web site www.ascbio.com.

On April 13, 2018 The Company and NYMC executed an Addendum to the License Agreement which confirmed The Company's rights to commercialize a new Patent Pending (#62592957) on the same terms and conditions as apply to the original patent referred to above.

Earnings per Share

The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares, adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.

Dividends

The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during the current reporting periods.

Long Term Debt

As of June 30, 2018, The Company owed $23,647 to Morrell Instrument Company, Inc., being the outstanding equipment loan balance, the maturity date of which is December 1, 2021.

Stock Based Compensation

The primary focus is with transactions in which an entity obtains employee services, in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, "Accounting for Stock-Based Compensation," and supersedes Accounting Principles Board ("APB") Opinion No.25, "Accounting for Stock Issued to Employees," and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards, after the grant date, must be recognized. The Company has not adopted a stock option plan nor has it granted any stock options. The Company granted stock awards, at its par value (the cost thereof debited to Organization Costs), to its officers, directors and advisors for services rendered in its formation. Accordingly, no further stock-based compensation has been recorded to date.

Estimated Fair Value of Financial Instruments

ASC 820, "Fair Value Measurements", requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Development Stage C ompany

The Company's financial statements are prepared pursuant to the provisions F A S B Accounting Standards Board Codification Topic 915-10 ("Development Stage Entities"), which specifies the guidelines for identifying an entity in the development stage, addresses the applicability of generally accepted accounting principles (GAAP) to development stage entities, and provides guidance on financial reporting requirements for development stage entities, including additional information required to be presented in the basic financial statements of development stage entities.

A development stage entity will typically be devoting most of its efforts to activities such as the following:

1. **Financial planning**
2. **Raising capital**
3. **Exploring natural resources**
4. **Developing natural resources**
5. **Research and development**

7. **Acquiring property, plant, equipment, or other operating assets, such as mineral rights**

8. Recruiting and training personnel

9. Developing markets

10. Starting up production

Note: ASC 915 is being superseded by FASB Accounting Standards Update No. 2014-10. ***Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.*** The amendments made by ASU 2014-10 are effective for public business entities for annual reporting periods beginning after December 15, 2014, and interim periods therein. For other entities, the amendments are effective for annual reporting periods beginning after December 15, 2014, and for interim reporting periods beginning after December 15, 2015.

Specifically, ASU 2014-10:

Removes **ASC 915** in its entirety from the ***FASB Accounting Standards Codification***

Deletes the guidance in **ASC 810** on how to assess whether a DSE has sufficient equity at risk in the evaluation of whether the DSE is a variable entity.

Clarifies that all entities, including entities that have not begun operations, should provide the risk and uncertainty disclosures required in **ASC 275**.

The ASU will be applied retrospectively and will be effective for business entities in interim and annual periods beginning after December 15, 2014. The requirements will be effective for non-public entities for annual periods beginning after December 15, 2014, and interim and annual periods thereafter. However, both public and non-public entities will have additional time to adopt the amendments to AC 810. Early adoption is permitted in all cases.

Full details and further information can be found on the FASB web site, www.fasb.org.

Start-up Costs

Risks and Uncertainties

The Company is subject to substantial business risks and uncertainties inherent in starting a new business. There are no assurances That the Company will be able to generate sufficient revenues or obtain sufficient funding necessary to continue in business.

NOTE 3- Going Concern

In August 2017, in accordance with its agreement with Stem Cell Development Fund, LLC (see OTC Press Release) ASC started to receive funds in accordance with the term of that agreement. As of May 80, 2018, The Company had received $1,211,275 of the $1,544,000 provided for in the agreement.

In view of the on-going negotiations with other funding sources, it was decided by mutual agreement to terminate the agreement with Stem Cell Development Fund, LLC as of May 8, 2018 and to issue 627,604 shares of Common Stock being the pro-rata number of shares equivalent to the $1,211,275 raised as of that date.

The shares were issued from The Company's balance of Treasury Shares, thereby leaving the number of issued shares unchanged.

In order to continue to be considered a "going concern", the Company is currently planning an additional capital raise of $25m to be offered initially in the amount of $15m followed by a further $10m after one year. The offering statement is being prepared under the new SEC Regulation A + rules of Title 4 of the JOBS Act, which now allows "Private Placements" to be offered by way of general solicitation or advertising.

The raising of the minimum amount of $15m will enable the Company to move forward with large scale production of its MASC stem cells which will then be used to perform therapies on human subjects outside of the United States. Therapies will be performed under strictly controlled conditions in full conformity with FDA regulations and protocols.

The data thus produced will be used to support our applications to the FDA to move forward with Phase 1 and Phase 2 Clinical Trials in the United States.

Once our concept of tissue regeneration has been confirmed with human subjects, the raising of additional funds will become easier and the discussion as to whether or not the Company should be considered a "going concern:" will become moot.

It is Management's opinion that The Company is considered, for accounting purposes, as a "going concern" as described within the codification of the Federal Accounting Standards Board ("FASB"), including the FASB update No. 2014-15

NOTE 4- Provision for Income Taxes

We are subject to state and federal income taxes in the U.S. Significant judgment is required in evaluating our uncertain tax positions and determining our provision for income taxes. In accordance with FASB ASC Topic 740, *"Income Taxes,"* we provide for the recognition of deferred tax assets if realization of such assets is more likely than not.

The component of the Company's deferred tax asset as of June 30, 2018 and 2017 is as follows:

	2018	2017
Net operating loss carry forward	780,130	-
Valuation allowance	(780,130)	-
Net deferred tax asset	$ -	$ -

The Company commenced business, with zero assets and liabilities, under its current name on February 27, 2017, and did not pay any income taxes during the periods ended June 30, 2018.

Under ACS 740 *"Income Taxes,"* when it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carry-forwards, because management has determined that, as a Development Stage Company with insufficient capital to become operational or to prove the efficacy of its IP technology, that to do so at this time would be overly optimistic.

The potential Deferred Tax Asset would be approximately $163,827 based on the new 2018 corporate income tax rates (subject also to the 80% loss limitation described below). This decision will be reconsidered at the end of each subsequent quarter.

The new "Tax Cuts and Jobs Act" of December 2017 also changes the rules on NOL carry forward. The 20-year limitation was eliminated, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2018, will now be limited to 80 percent of taxable income.

NOTE 5- Stockholders Deficit

As of June 30, 2018, the shareholders net equity has increased from ($**720,974**) to $359,580) due to issuance of $1,211,275 of common shares and the deficit of $130,721 incurred in the 3 Months ended June 30, 2018.

NOTE 6- The Effect of Recently Issued Accounting Standards

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below. These are additional to ASB 2014-10 mentioned in note 2 above.

In January 2009, the FASB issued Accounting Standards Update No.2009-13 ("ASU 2009-13") "Revenue Recognition" (ASC 605), Multiple-Deliverable Revenue Arrangements a consensus of the FASB Emerging Issues Task Force ("EITF"). This ASU provides amendments to the criteria in FASB ASC 605-25 for separating consideration in multiple-deliverable arrangements. ASU 2009- 13 changes existing rules regarding recognition of revenue in multiple deliverable arrangements and expands ongoing disclosures about the significant judgments used in applying its guidance. It will be effective for revenue arrangements entered into or materially modified in the fiscal year beginning on or after June 15, 20 I 0. Early adoption is permitted on a prospective or retrospective basis. The adoption of FASB ASU 2009-13 did not have a material impact on the Company's financial statements.

In June 2009, the FASB issued FASB ASC 820-10, "Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly." This ASC provides additional guidance for estimating fair value in accordance with FASB ASC 820-10, when the volume and level of activity for the asset or liability have significantly decreased. This ASC also includes guidance on identifying circumstances that indicate a transaction is not orderly. This ASC is effective for interim and annual reporting periods that ended after June 15, 2009. The ASC does not require disclosures for earlier periods presented for comparative purposes at initial adoption. In periods after initial adoption, this ASC requires comparative disclosures only for periods ending after initial adoption. The adoption of FASB ASC 820-10 did not have a material impact on the Company's financial statements.

On July 1, 2009, the Company adopted updates issued by the Financial Accounting Standards Board (FASB) to the authoritative hierarchy of GAAP. These changes establish the FASB Accounting Standards Codification TM (ASC) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases (of the Securities and Exchange Commission ("SEC") under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification.

These changes and the Codification itself do not change GAAP. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on the Financial Statements.

In January 2010, the Financial Accounting Standards Board ("FASB") issued guidance to amend the disclosure requirements related to recurring, and nonrecurring, fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical assets or liabilities) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a roll forward of activities on purchases, sales, issuance, and settlements of assets and liabilities measured using significant unobservable inputs. Other than requiring additional disclosure, adoption of this new guidance did not have any material impact on the financial statements.

In January 2010, the FASB issued an amendment to ASC 505, Equity, where entities that declare dividends to shareholders that may be paid in cash or shares at the election of the shareholders are considered to be a share issuance that is reflected prospectively in EPS, and is not accounted for as a stock dividend. This standard is effective for interim and annual periods ending on or after December 15, 2009 and is to be applied on a retrospective basis. The adoption of this standard is not expected to have a significant impact on the Company's financial statements.

On February 24, 2010, the FASB issued guidance in the "Subsequent Events" topic of the FASC to provide updates including:
l) requiring the company to evaluate subsequent events through the date in which the financial statements are issued; (2) amending the glossary of the "Subsequent Events" topic to include the definition of "SEC filer" and exclude the definition of "Public entity"; and (3) eliminating the requirement to disclose the date through which subsequent events have been evaluated. This guidance was prospectively effective upon issuance. The adoption of this guidance did not impact the Company's results of operations of financial condition.

The Company has reviewed and implemented all new accounting pronouncements issued between 2011 and 2017 to date that may have a future impact on its Financial Statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that have a material impact on its financial position or results of operations at this time, and to re-state these pronouncements would serve no purpose.

The following FASB Pronouncements were issued in the 6 Months ended June 30, 2018

- Update 2018-08—Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made

- Update 2018-07—Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

- Update 2018-06—Codification Improvements to Topic 942, Financial Services—Depository and Lending.

- Update 2018-05—Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)

- Update 2018-04—Investments—Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 117 and SEC Release No. 33-9273 (SEC Update)

- Update 2018-03—Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities

- Update 2018-02—Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

- Update 2018-01—Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842

After reviewing these pronouncements, management is of the opinion that they have no material impact on The Company's financial position at this time.

NOTE 7- Treasury Shares

Upon the initial award of 8,000,000 "Control Group" common shares from the Bankruptcy judge, the Company designated 2,400,000 common shares to be issued as Treasury Shares. These shares were to be used for three primary purposes, as follows;

1) To be sold to investors in order to provide an initial funding for development purposes.
2) To be issued to future executive officers, such as a Chief Medical Officer as part of an incentive remuneration package.
3) To be used, in lieu of cash, at Management's discretion to compensate individuals or entities providing services to the Company during the development period.

As noted in Note 3 above, 627,604 Treasury Shares were recently issued to Stem cell Develop0ment Fund, LLC in exchange for $1,211,275 of development funds.

NOTE 8- Subsequent Events

The Company evaluated all events or transactions that occurred after June 30, 2018 through the date of this filing in accordance with FASB ASC 855 "Subsequent Events". The Company determined that it does not have any additional subsequent event requiring recording or disclosure.

This concludes the footnotes, and the Company Information and Disclosure statement follows hereto, and is a part hereof.